-
Health and WellnessNew, long-acting PrEP injection found to effectively prevent HIV transmission
A major clinical trial shows getting a shot every other month can be just as effective as taking a daily pill.
-
Health and WellnessChicago doctor says coronavirus patients treated with antiviral drug “have done really well”
“We have seen people come off ventilators a day after starting therapy.”
-
News (USA)The Trump administration just sued the maker of PrEP for profiting off taxpayer-funded research
The government says it owns some patents on the HIV medication regimen & is owed royalties.
-
News (USA)Gilead to offer 11 years of free PrEP to up to 200,000 people in need
This move will allow the medication to get into many more hands.
-
Health and WellnessA generic version of PrEP will be available next year
Activists hailed the earlier than expected release, calling it “a victory for the LGBTQ+ community, for HIV activists, and for U.S. taxpayers.”
-
Health and WellnessPoliticians are asking the feds to ‘break the patent’ on PrEP to make it more widely available
Because the drug was developed using federal funds, the National Institute of Health has the option of breaking the patent and allowing generic versions to come to market.
-
Health and WellnessGilead’s new TV ads for PrEP will be unique. They include gay & trans people.
The first ad features three groups heavily affected by HIV: youth of color, transgender women, and gay men.
-
News (USA)FDA approves generic Truvada — but there’s a catch
The move took advocates by surprise, since it wasn’t expected until 2021. However, the announcement has led to confusion about how soon it might be available.
-
News (USA)Report: Drug maker was focused on profits, not patients
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease.
-
News (USA)FDA rejects two HIV drugs from Gilead Sciences
FOSTER CITY, Calif. — Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company’s manufacturing facilities.
